Effects on baseline DAS28 (points) | Effects on annual rate of change in DAS28 (points/year) | |||||
P value | Prevaccination | P value | Post vaccination | P value | ||
Intercept | 2.644±0.279 | <0.001 | 0.029±0.059 | 0.620 | −1.748±1.366 | 0.201 |
Gender (ref. woman) | −0.790±0.105 | <0.001 | 0.002±0.021 | 0.922 | 0.050±0.512 | 0.922 |
Age at vaccination (per year) | 0.007±0.005 | 0.115 | −0.001±0.001 | 0.376 | 0.025±0.023 | 0.275 |
Targeted therapy at vaccination (ref. TNF-i) | 0.302±0.091 | 0.001 | −0.107±0.031 | <0.001 | 0.617±0.549 | 0.261 |
*Plus-minus values represent means±SE.
PsA, psoriatic arthritis; ref., reference; TNF-i, tumour necrosis factor inhibitor.